Tumor-associated antigens and neoantigens expressed by autologous renal cell carcinoma cells (TAA/Neoantigen (RCC))

Tumor-associated antigens (TAAs) and neoantigens expressed by autologous renal cell carcinoma (RCC) cells represent a personalized suite of therapeutic targets used in cancer immunotherapy. TAAs are proteins such as Carbonic Anhydrase IX (CAIX/G250) or 5T4 that are overexpressed in tumor tissue, while neoantigens are novel peptides resulting from tumor-specific somatic mutations, making them highly specific to the individual patient's malignancy (Source: PubMed, PMID: 28945323). These antigens are typically utilized in the production of autologous dendritic cell vaccines, such as Rocapuldene-T, or personalized peptide vaccines designed to educate the patient's immune system to recognize the unique molecular signature of their cancer (Source: Nature Reviews Urology, 2019). By targeting these antigens, therapies aim to induce a robust cytotoxic T-cell response capable of infiltrating the tumor microenvironment and overcoming local immunosuppression (Source: Journal of Clinical Oncology, 2016). While neoantigens offer high specificity and reduced risk of central tolerance, the inherent heterogeneity of RCC poses a significant challenge, often requiring the targeting of multiple antigens simultaneously to prevent tumor escape and ensure long-term efficacy (Source: Science, 2017).

Other names

RCC tumor antigensAutologous renal cancer antigensTumor-specific antigens (TSA)Renal cell carcinoma neoantigensPatient-specific RCC antigens

Induction of an adaptive immune response through the presentation of tumor-specific or tumor-associated peptides to T-cells via MHC molecules, leading to the activation and expansion of cytotoxic T-lymphocytes (CTLs) that specifically target and lyse renal cell carcinoma cells.